Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18419678 | 0.76 | TAAR1 (0.33) | TSHRTAAR1 | |
| SCHEMBL21736799 | 0.74 | — | — | |
| SCHEMBL5510318 | 0.74 | TSHR (0.32) | TSHRTAAR1KCNH2 | |
| SCHEMBL16838143 | 0.72 | RAPGEF4 (0.35) | MEN1KMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL8562252 | 0.72 | NR1H4 (0.34) | MEN1KMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL24594969 | 0.71 | RAPGEF4 (0.37) | MEN1KMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL20459508 | 0.69 | CA1 (0.44) | MEN1KMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL16838144 | 0.69 | MAT2A (0.34) | MEN1KMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL25082732 | 0.69 | KCNH2 (0.34) | TSHRMAT2AKCNH2 | |
| SCHEMBL25908497 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018053040-A1 | TREATMENT OF MULTIPLE SCLEROSIS WITH CHS-131 | INTEKRIN THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |